Anschel Technology Inc. (AT) was incorporated in 2011, on the background of 7 years of clinical experience and research to develop and bring to market a novel medical device. The SightSaver™ is a FDA approved and patented (#’s 7,862,516; 8,777,405) device for eliciting visual evoked potentials. Several thousand people per year in the United States develop post-operative visual loss (POVL) following non-ocular procedures. Current approaches for addressing this problem have failed due to the use of low quality, non-hygienic, uncomfortable, and unreliable visual stimulators. The SightSaver™ provides a hygienic, safe, comfortable, and effective alternative.
Company founder David Anschel grew up in upstate NY graduating summa cum laude from SUNY Buffalo with a degree in Biological Sciences. Following college he received an award from the Department of Energy to research tree ecophysiology at Lawrence Livermore National Laboratory, prior to his enrollment in medical school at New York University. Dr. Anschel graduated with Honors in Physiology and Neuroscience and moved to Boston where he completed Internal Medicine Internship and Neurology Residency at Harvard – Beth Israel Deaconess/Boston Children’s Hospitals. Dr. Anschel’s further training was at Stanford University where he completed a 2 year fellowship in Clinical Neurophysiology and Epilepsy. Formerly an Assistant Professor at SUNY Stony Brook and Associate Scientist at Brookhaven National Laboratory, he is now Director of Clinical Neurophysiology and the Founding Director of the Comprehensive Epilepsy Center of Long Island at St. Charles Hospital in Port Jefferson, NY. He is the author of over 70 scientific publications, as well as several books and chapters. Dr. Anschel has consulted for more than 100 companies and firms including major research, private equity, law, pharmaceutical, and medical device companies.
Company’s Keywords:
<0
<
<2011